Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. [electronic resource]
Producer: 19990415Description: 1210-3 p. digitalISSN:- 0041-1345
- Adult
- Aged
- Antibodies, Monoclonal -- therapeutic use
- Basiliximab
- Cadaver
- Cyclosporine -- therapeutic use
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Graft Rejection -- prevention & control
- Graft Survival
- Histocompatibility Testing
- Humans
- Immunosuppressive Agents -- therapeutic use
- Kidney Transplantation -- immunology
- Living Donors
- Male
- Middle Aged
- Recombinant Fusion Proteins
- Retrospective Studies
- Survival Analysis
- Tissue Donors
- United States
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.